Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.31 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28976609 | 0.87 | TEAD1 (0.36) | KDM1ACHRNA7EPHX2TEAD1TEAD4 | |
| SCHEMBL30281179 | 0.85 | — | — | |
| SCHEMBL28976633 | 0.73 | DGAT1 (0.38) | PARP1PARP2 | |
| SCHEMBL28976697 | 0.73 | SCN10A (0.37) | KDM1APARP1PARP2CHRNA7 | |
| SCHEMBL30281265 | 0.72 | JAK2 (0.35) | KDM1APARP1PARP2OPRM1 | |
| SCHEMBL30281156 | 0.71 | — | — | |
| SCHEMBL28976577 | 0.70 | SCN10A (0.33) | OPRM1 | |
| SCHEMBL28976940 | 0.70 | PARP1 (0.32) | PARP1PARP2 | |
| SCHEMBL28974169 | 0.69 | KDM1A (0.36) | KDM1APARP1PARP2OPRM1TEAD1 | |
| SCHEMBL15566755 | 0.65 | PARP1 (0.32) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317962-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |